| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a … JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, ... The lancet oncology 15 (11), 1195-1206, 2014 | 891 | 2014 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 624* | 2019 |
| Guidelines for the diagnosis and management of multiple myeloma 2011. JM Bird, RG Owen, S D'Sa, JA Snowden, G Pratt, J Ashcroft, K Yong, ... British journal of haematology 154 (1), 2011 | 446 | 2011 |
| High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution S Chakrabarti, S Mackinnon, R Chopra, PD Kottaridis, K Peggs, ... Blood, The Journal of the American Society of Hematology 99 (12), 4357-4363, 2002 | 428 | 2002 |
| Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen R Chakraverty, K Peggs, R Chopra, DW Milligan, PD Kottaridis, ... Blood, The Journal of the American Society of Hematology 99 (3), 1071-1078, 2002 | 400 | 2002 |
| Multiple myeloma: patient outcomes in real‐world practice K Yong, M Delforge, C Driessen, L Fink, A Flinois, S Gonzalez‐McQuire, ... British journal of haematology 175 (2), 252-264, 2016 | 309 | 2016 |
| Time to redefine myeloma G Pratt, S Bowcock, A Chantry, G Cook, G Jackson, M Lai, E Low, ... British Journal of Haematology 171 (1), 1-10, 2015 | 287 | 2015 |
| Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO NJ Booth, AJ McQuaid, T Sobande, S Kissane, E Agius, SE Jackson, ... The Journal of Immunology 184 (8), 4317-4326, 2010 | 282 | 2010 |
| Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses KS Peggs, K Thomson, DP Hart, J Geary, EC Morris, K Yong, ... Blood 103 (4), 1548-1556, 2004 | 274 | 2004 |
| Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders JA Pérez-Simón, PD Kottaridis, R Martino, C Craddock, D Caballero, ... Blood, The Journal of the American Society of Hematology 100 (9), 3121-3127, 2002 | 263 | 2002 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 255 | 2021 |
| Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of CXC chemokines and transmit virus by direct neutrophil-endothelial cell contact and during … JE Grundy, KM Lawson, LP MacCormac, JM Fletcher, KL Yong Journal of Infectious Diseases 177 (6), 1465-1474, 1998 | 255 | 1998 |
| Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial S Trudel, N Lendvai, R Popat, PM Voorhees, B Reeves, EN Libby, ... The Lancet Oncology 19 (12), 1641-1653, 2018 | 236 | 2018 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 195 | 2021 |
| Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set A Chari, MK Samur, J Martinez-Lopez, G Cook, N Biran, K Yong, ... Blood, The Journal of the American Society of Hematology 136 (26), 3033-3040, 2020 | 186 | 2020 |
| High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell … G Cook, C Williams, JM Brown, DA Cairns, J Cavenagh, JA Snowden, ... The lancet oncology 15 (8), 874-885, 2014 | 182 | 2014 |
| Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model C Kyriakou, N Rabin, A Pizzey, A Nathwani, K Yong haematologica 93 (10), 1457-1465, 2008 | 160 | 2008 |
| An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma L Lee, B Draper, N Chaplin, B Philip, M Chin, D Galas-Filipowicz, ... Blood, The Journal of the American Society of Hematology 131 (7), 746-758, 2018 | 159 | 2018 |
| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Journal of Clinical Oncology 38 (21), 2380, 2020 | 142 | 2020 |
| Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial MT Drayson, S Bowcock, T Planche, G Iqbal, G Pratt, K Yong, J Wood, ... The Lancet Oncology 20 (12), 1760-1772, 2019 | 142 | 2019 |
Gordon CookUniversity of LeedsEmail verificata su leeds.ac.uk
